Xtandi reduced the risk of death by 34 percent in men with metastatic hormone sensitive prostate cancer in a Phase III study.
List view / Grid view
androgen deprivation therapy (ADT)
Data shows metastatic castration-sensitive prostate cancer patients treated with Erleada® (apalutamide) were 35 percent less likely to die and had maintained quality of life.
A Phase III clinical trial has shown that metastatic prostate cancer improved through the use of a combination therapy with enzalutamide...